GEN-MKT-18-7897-A
Feb 12, 2025 | Blogs, Discovery, Echo MS, Pharma, QA/QC | 0 comments
Read time: 2 minutes
On average, it takes 10-15 years and 1-2 billion dollars to approve a new pharmaceutical for clinical use. Since approximately 90% of new drug candidates fail in clinical development, the ability to make early, informed and accurate decisions on the safety and efficacy of new hits and leads is key to increasing the chances of success.
To achieve this drug discovery assays require speed and accuracy, but often scientists must compromise on one of these requirements to cope with the thousands of samples that need to be analyzed.
The Echo® MS+ system allows pharmaceutical companies to make data-driven decisions early in the drug discovery process, saving time and money, and potentially getting their drug to market faster than with more traditional approaches. Common analytical techniques such as LC-MS or fluorescence are limited by either sample throughput or accuracy of results.
Learn more >
The Echo® MS+ system uses acoustic ejection mass spectrometry (AEMS) technology. Samples are placed into a compatible well plate which is held in the Echo® MS+ system’s autosampler. Here sound energy is applied to the bottom of each well individually. The sound energy causes reproducible droplets to be ejected from the well for capture in a carrier solvent of the OPI for dilution and transfer to the mass spectrometer’s source. From this point, the diluted sample is ionized using conventional electrospray ionization, ready for detection.
Watch video >
Produced by certain moulds, thriving in crops such as grain, nuts and coffee, mycotoxins have contaminated agriculture and food production industries for a long time. To intensify the challenge, mycotoxins are resilient, not easily broken down and ensuring the safety of food supply chains requires comprehensive solutions and we are here to share those solutions with you.
Electron-Activated Dissociation (EAD) is transforming the fields of metabolomics and lipidomics by providing enhanced fragmentation techniques that offer deeper insights into molecular structures. In September, Technology Networks hosted a webinar, “Enhancing Mass-Based Omics Analysis in Model Organisms,” featuring Dr. Valentina Calabrese from the Institute of Analytical Sciences at the University of Lyon. Valentina shared her insights on improving omics-based mass spectrometry analysis for toxicology studies using model organisms, particularly in metabolomics and lipidomics. This blog explores the additional functionalities EAD offers, its benefits in untargeted workflows, its incorporation into GNPS and molecular networking, and the future role it could play in these scientific domains.
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) has gained significant attention in the clinical laboratory due to its ability to provide best-in-class sensitivity and specificity for the detection of clinically relevant analytes across a wide range of assays. For clinical laboratories new to LC-MS/MS, integrating this technology into their daily routine operations may seem like a daunting task. Developing a clear outline and defining the requirements needed to implement LC-MS/MS into your daily operations is critical to maximize the productivity and success of your clinical laboratory.
Posted by
You must be logged in to post a comment.
Share this post with your network